ClinicalTrials.gg
Not yet recruitingNCT07714187Updated Jul 20, 2026

A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides

A Phase 1 interventional study of Duvelisib in Mycosis Fungoides and Cutaneous T-cell Lymphoma, sponsored by SecuraBio. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by SecuraBio · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 360 studies in Mycosis Fungoides with a site in United States — 24 open to participants now, 36 under way, none of them phase 3. Mycosis Fungoides · United States.

Planned enrollment
141st of 279
30 · median 32
Started
2027
with 1 other
Phase 1
131 of 360
8 open now
Primary completion
2028-10
later than 25 of 35 live
Registered
359th of 360
by date

Among the 360 studies in Mycosis Fungoides with a site in United States, this one is the 141st largest by planned enrollment of the 279 interventional ones that give a count, is one of 2 that started in 2027, is one of 131 in phase 1, reaches primary completion later than 25 of the 35 other live ones, and was the 359th registered.

Mycosis Fungoides

447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.

Browse Mycosis Fungoides studies →

Open to participants now

24 of the 360 studies in Mycosis Fungoides with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Mycosis Fungoides studies recruiting now, 25 (83%) set no upper age limit and 1 (3%) stops at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 360 studies in Mycosis Fungoides with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and preliminary efficacy of duvelisib topical gel in participants with early-stage mycosis fungoides.

03

Conditions studied

  • Mycosis Fungoides
  • Cutaneous T-cell Lymphoma

Keywords

  • Early-stage mycosis fungoides
  • Duvelisib
  • Topical
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have a clinical diagnosis of Stage IA, Stage IB, or Stage IIA mycosis fungoides (cutaneous T-cell lymphoma), without lymphadenopathy (≥1.5 centimeters).
  • Have 3 to 5 active, treatment-accessible mycosis fungoides lesions; ulcerated lesions and lesions to the face, neck, inguinal folds and intergluteal cleft are not considered suitable for administration of study drug.
  • Have baseline organ function (without transfusion support within 30 days of Cycle 1 Day 1) as defined by the protocol.

Key Exclusion Criteria:

  • Have Stage IIB to IVB mycosis fungoides or Sezary syndrome.
  • Have histopathologically confirmed lymph node involvement.
  • Received systemic treatment with a phosphoinositide 3-kinases inhibitor in the 60 days prior to starting study drug.
  • Received topical or other topical treatment (for example, nitrogen mustard) on mycosis fungoides lesions in the 2 weeks prior to starting study drug. Participants who receive such agents may become eligible for the study after a 14-day .
  • Received systemic steroids, (for example, cyclosporine, prednisone), psoralen ultraviolet A radiation therapy, narrow-band ultraviolet B light therapy, carmustine or other systemic therapies for mycosis fungoides in the 3 weeks prior to starting study drug.
  • Received electron beam irradiation within the 3 months prior to starting study drug.

Note: other protocol-defined criteria apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Duvelisib

    Drug: Duvelisib

Interventions

  • Topical gel

    Also known as: SBI-0145

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Baseline through Day 114

  2. Local Skin Reactions to Duvelisib Topical Gel

    Local skin reactions will be measured as a local skin reaction score using a four-point post-treatment assessment severity scale.

    Time frame: After each treatment administration up to Day 114

  3. Maximum Tolerated Dose (MTD) of Duvelisib Topical Gel

    Time frame: Up to 28 days

  4. Recommended Phase 2 Dose (RP2D) of Duvelisib Topical Gel

    Time frame: Up to 28 days

Secondary outcomes

  1. Pharmacokinetics: Plasma Concentration of Duvelisib Topical Gel

    Time frame: Days 1, 2, and 28 (pre-dose, up to 6 hours post-dose)

  2. Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Duvelisib Topical Gel

    Time frame: Days 1, 2, and 28 (pre-dose, up to 6 hours post-dose)

  3. Pharmacokinetics: Time to Maximum Plasma Concentration (Tmax) of Duvelisib Topical Gel

    Time frame: Days 1, 2, and 28 (pre-dose, up to 6 hours post-dose)

  4. Pharmacokinetics: Area Under the Curve (AUC) of Duvelisib Topical Gel

    Time frame: Days 1, 2, and 28 (pre-dose, up to 6 hours post-dose)

  5. Proportion of Treated Lesions Achieving >50% Improvement from Baseline Based on Modified Composite Assessment of Index Lesion Severity (mCAILS) Score

    Time frame: Baseline through Day 114

  6. Number of Participants Achieving a ≥50% Reduction from Baseline in Total mCAILS Score

    Time frame: Baseline through Day 114

  7. Change from Baseline in Total Modified Severity-weighted Assessment Tool (mSWAT) Score

    Time frame: Baseline, Day 114

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Oct 2028, 21 months later.

Of 29 phase 1 interventional studies under Mycosis Fungoides, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 80. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 20, 2026
StartEst.
Jan 2027
Primary completionEst.
Oct 2028
CompletionEst.
Jan 2029
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07714187
Lead sponsor
SecuraBio
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Jan 2027 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Jul 20, 2026

Study contacts

Medical Director
Contact
TopicalStudy@securabio.com
1-858-251-1414
Reuven Chantre, MD
study director · Secura Bio, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Duvelisib

Start the discussion